Fibromyalgia and the Nervous System

Why every fibromyalgia test comes back normal

Fibromyalgia affects a global mean of 2.7 percent of people, and for decades most of them were told nothing was wrong. The tests were built to find damaged parts, and fibromyalgia has no damaged part. It has a mis-set regulator.

A person comes in hurting nearly everywhere. The pain has lasted months. Sleep gives nothing back. Thinking has gone soft at the edges. Every test that gets ordered comes back normal, and somewhere in that sequence the conversation quietly changes from what is wrong with you to whether anything is.

That story has repeated itself several million times. A worldwide review of prevalence studies by the Brazilian neurologist Luiz Paulo Queiroz put the global mean prevalence of fibromyalgia at 2.7 percent, with individual study estimates ranging from 0.4 percent to 9.3 percent. It is one of the most common reasons a person is referred to a rheumatologist. It is also, by a wide margin, one of the most disbelieved conditions in modern medicine.

The lesion model had only two answers, and both were wrong

The disbelief had a logic to it, and naming the logic is what dissolves it. Medicine learned to find disease by finding the broken part. A lesion, a tumor, an infection, an inflamed joint, a torn tendon, an antibody attacking a tissue.

Each of those leaves a fingerprint that a machine or a laboratory can read. The whole diagnostic apparatus was built on that premise, and it has been magnificently successful. Fibromyalgia hands that apparatus nothing at all. The muscles are normal. The joints are normal. The nerves, on the standard tests, are normal. Inflammatory markers are normal.

From inside the lesion model there are only two available conclusions. Either the test is missing something, or the patient is imagining it. For roughly thirty years, many people were handed the second conclusion. What was actually happening was simpler and stranger. The illness was real, and it lived in a place the tests were never designed to look.

The tests were built to find a broken part. Fibromyalgia has no broken part. It has a mis-set regulator, and no scanner has ever been designed to photograph a setting.

The modern clinical picture is well described. The rheumatologist Daniel Clauw has spent his career studying why some people hurt more than others from the same stimulus. In a widely read clinical review of fibromyalgia, he laid the case out in a line.

Fibromyalgia is a disorder of pain processing in the central nervous system, rather than a disease of the tissues where the pain is felt. That single sentence is the hinge everything below turns on. To understand it, you have to understand something most people have never been taught: what pain actually is.

Pain is a protective output with a sensitivity setting

Soldiers have walked off battlefields with catastrophic wounds and felt almost nothing until they reached safety. People feel agony in limbs amputated years earlier. Roughly a third of adults have visible disc degeneration on a spine scan and no pain at all. Tissue state and pain experience are loosely related in both directions, and fibromyalgia lives inside that looseness.

Almost everyone carries the same mental model of pain, and it is the wrong one. In that model, pain is a measurement. Tissue gets hurt, a signal travels up like a phone call, and the amount of pain you feel tells you the amount of damage you have.

More damage, more pain. No damage, no pain. It feels obviously true, the way it once felt obviously true that the sun moves across the sky. The exceptions above are not rare curiosities. They are the rule showing through.

Melzack and the phantom limb

The Canadian psychologist Ronald Melzack spent decades trying to explain that looseness, and the phantom limb was the case that broke the old model for him. A person whose arm is gone cannot be receiving signals from the arm. Yet the pain is vivid, located, and often severe.

Melzack set out his conclusion in an account of pain and the neuromatrix in the brain. Pain is produced by a widely distributed network in the brain rather than delivered to it from the body. Incoming signals from tissue can trigger that network and shape what it produces. They do not constitute the pain.

Here is the reframe. Pain is an output, and its job is protection. Your nervous system runs a continuous, mostly unconscious appraisal of how dangerous your current situation is to your body. It gathers evidence from the tissues, from your position, from your history, from your expectations, from how threatened you already feel. Then it produces an experience calibrated to make you protect yourself. Pain is the alarm the system decides to sound, and like every alarm it has a sensitivity setting.

This is now standard teaching in pain science rather than a fringe position. The Australian pain researcher Lorimer Moseley has studied whether explaining pain biology to patients changes their pain. Reviewing fifteen years of that teaching approach with the physiotherapist David Butler, he reported what it does.

Teaching people to understand pain as a protective output increases what they know about pain biology and lowers catastrophizing. It also produces short-term reductions in pain and disability. Understanding the alarm changes the alarm. No purely mechanical readout would behave that way.

Hold that idea, because everything in fibromyalgia follows from it. If pain is an output with a sensitivity setting, then a person can hurt terribly with nothing wrong in the tissue. All that is required is that the setting has moved.

Four structures set the volume of pain

Between a nerve ending in the skin and the experience of pain sit a spinal checkpoint with a gain control and a descending brake from the brainstem. Neither is fixed, and fibromyalgia is what happens when both settings drift the wrong way and stay there.

First, the sensors. Scattered through your skin, muscles, joints, and organs are nerve endings called nociceptors. A nerve is a living wire, a bundle of fibers carrying messages as tiny electrical pulses. A nociceptor is the kind of wire that fires when something potentially damaging happens nearby, such as heat, pressure, stretch, or chemicals released by injured cells. The distinction matters. A nociceptor sends a danger signal. Whether pain gets built from that signal is decided farther in.

Second, the first checkpoint. Those signals travel to the dorsal horn, a relay station in the back of the spinal cord where incoming fibers hand off to the next set of cells. This is the single most important structure on this page. The dorsal horn does far more than splice wires together. It is a switchboard with a gain control. The state of the cells sitting there sets the strength of what leaves, and that state can change.

Third, the descending brake. Your brainstem, the stalk where the brain meets the spinal cord, sends fibers back down the cord to that same checkpoint. Those fibers can turn the gain down, releasing the body's own opioid and noradrenaline-based chemistry to quiet incoming traffic.

This is the system that lets an athlete finish a play on a fractured foot. The same descending pathways can also turn the gain up when the brain judges that more vigilance is warranted. The brake and the accelerator sit on the same pedal assembly.

Fourth, the construction. What survives the checkpoint travels up to the thalamus and then out to a network of regions across the cortex and deeper brain, where the experience is actually assembled. Sensation, location, emotional weight, meaning, and urgency all get built in there. That assembly is what you feel.

Two places where the signal is multiplied

Now the point of all four pieces. Between the tissue and the experience there are at least two places where the signal is multiplied or divided: the spinal checkpoint and the descending brake. Neither of them is fixed. Both are settings. If those settings drift upward and stay there, the tissue can be pristine and the experience can be agony, with no contradiction anywhere in the system. That drift has a name, and a discoverer.

Central sensitization: the spinal cord raises its own gain

In 1983 Clifford Woolf showed that after injury the spinal cord itself becomes more excitable, so that gentle input produces a full defensive response. The amplification he found in a spinal reflex is the mechanism that makes a bedsheet hurt in fibromyalgia.

Woolf, then a young neurobiologist in London, was studying what injury does to spinal reflexes. The question he was asking was narrow and technical. An animal becomes more sensitive to touch around an injury. Is that entirely explained by the injured tissue becoming more sensitive, which was the standard assumption, or is some of it happening farther in?

He measured the flexion reflex, the spinal withdrawal response that pulls a limb away from harm, before and after an injury, and he found something the standard assumption could not accommodate. The reflex became far easier to trigger, and the rise in excitability could not be explained by the injured tissue alone.

Part of it arose from a change in the activity of the spinal cord itself. Gentle input that previously produced nothing now produced a full defensive response. The amplification was happening in the cord. Woolf published this as evidence for a central component of post-injury pain hypersensitivity, and it changed the field. The pain system was not a passive cable. It could rewrite its own gain.

The machinery of the raised gain

The phenomenon acquired a name, central sensitization, and Woolf spent the following decades characterizing it. Writing with the neuroscientist Michael Salter in a paper titled Neuronal plasticity: increasing the gain in pain, he described the machinery in detail. Repeated or intense input drives calcium into the checkpoint neurons. Receptors are modified and multiplied, and inhibitory cells lose their grip. The system installs an amplifier and then maintains it.

In his later synthesis of central sensitization and what it means for diagnosis and treatment, Woolf defined it as amplification of neural signaling within the central nervous system that produces pain hypersensitivity. That account also brings in glial cells, the immune-like support cells of the nervous system, which join the process and help hold the neurons in an excitable state. Three consequences follow, and every one of them describes a fibromyalgia patient's daily life.

Now put that against the diagnostic apparatus from the first section. A raised gain has no size, no shape, and no density. It does not absorb x-rays, take up contrast, or leak a protein into the blood. An MRI photographs structure exquisitely and cannot photograph a setting. This is the whole reason the tests come back normal in fibromyalgia, and it is a straightforward consequence of what kind of change this is.

Nociplastic pain: the category fibromyalgia forced into existence

The field eventually formalized the point. In 2016 a group led by the Swedish pain researcher Eva Kosek asked whether the two existing categories of pain were enough. The paper was titled Do we need a third mechanistic descriptor for chronic pain states? Medicine had nociceptive pain, meaning pain from tissue damage, and neuropathic pain, meaning pain from a damaged nerve. Fibromyalgia is neither.

The third descriptor, adopted by the International Association for the Study of Pain and now called nociplastic pain, covers pain that arises from altered nociception without evidence of tissue damage or nerve lesion.

A 2021 review in the Lancet on nociplastic pain and the common conditions it explains, led by the rheumatologist Mary-Ann Fitzcharles, placed fibromyalgia as the prototype of that category. The category exists because these patients would not fit in the other two. They were right the whole time, and the map had to be redrawn around them.

Six laboratories measured the raised gain in fibromyalgia patients

Central sensitization could have remained a rodent laboratory phenomenon invoked to excuse a puzzling illness. Instead, over three decades, the amplification has been measured in living fibromyalgia patients by six independent methods, each reading a different part of the machinery.

The checkpoint stays wound up

There is a normal phenomenon called wind-up, or temporal summation. If identical mildly painful heat pulses are delivered at a steady rhythm, the perceived pain climbs across the first several pulses even though the stimulus never changes. That climb is the spinal checkpoint summing input.

The rheumatologist Roland Staud tested whether that summation behaves differently in fibromyalgia. His 2001 study of abnormal sensitization and temporal summation of second pain found that patients wound up faster, to higher levels, and stayed wound up longer. The amplifier was directly observable in the response curve.

The brain responds as though the stimulus were stronger

The pain researcher Richard Gracely, working with Clauw, designed an experiment to separate real neural amplification from a tendency to report pain readily. He applied controlled pressure to the thumbnail while participants lay in a functional MRI scanner, which tracks blood flow as a proxy for regional brain activity. The 2002 imaging evidence of augmented pain processing in fibromyalgia was decisive in design.

At identical pressures, patients reported far more pain and showed far more activation in pain-processing regions. When the pressure delivered to the controls was raised until their reported pain matched what the patients reported, the activation patterns matched too. The brains were receiving an amplified signal rather than exaggerating a report.

The pain network never fully stands down

The neuroscientist Vitaly Napadow examined the brain's resting connectivity, meaning which regions idle in sync when a person is doing nothing at all. His 2010 study of intrinsic brain connectivity in fibromyalgia found the default mode network, the system that runs during rest and self-referential thought, abnormally coupled to the insula, the region central to body sensation. The strength of that coupling tracked how much spontaneous pain the person was in. Even at rest, the body-monitoring system had not let go.

The chemistry of the excitable state is present

The pain researcher Richard Harris used magnetic resonance spectroscopy, which measures chemical concentrations in living brain tissue rather than anatomy, and found in 2009 that elevated insular glutamate in fibromyalgia tracked experimental pain sensitivity. Glutamate is the nervous system's main excitatory signal.

More of it in that region means a more excitable region. Fifteen years earlier, the rheumatologist I. Jon Russell sampled spinal fluid directly and reported threefold elevated levels of substance P, a transmitter released by incoming danger fibers, in patients compared with controls. The excitatory traffic in the cord was measurably heavier.

The immune-like cells are switched on

Woolf's mechanism predicted glial involvement. A multi-site positron emission tomography study led by the imaging scientist Daniel Albrecht used a tracer that binds a protein expressed by activated glia. In 2019 it found brain glial activation in fibromyalgia patients across two independent research groups. Classical inflammation of the sort a blood test screens for stays absent. The nervous system's own support cells run in an activated state, which is precisely what maintains a raised gain.

The brake has failed

A healthy nervous system can quiet its own pain. Give it a strong enough noxious challenge and the descending brake engages, damping what is felt. The researcher Nancy Julien tested that inhibitory capacity in fibromyalgia, using ascending and descending sequences of thermal stimulation along with a cold-water immersion. In 2005 she found that widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Patients did not show the normal drop. The accelerator is up and the brake has gone soft.

Six different methods, six different laboratories, one convergent finding. The pain system in fibromyalgia runs at a raised gain with a weakened brake. The normal blood work was never evidence against the illness. It was evidence that the illness lives one level up from where the blood work looks.

Why the fibromyalgia criteria kept changing

Three revisions in 26 years moved the definition of fibromyalgia from eighteen tender points on a muscle exam to a scored regulatory state: pain in many regions, fatigue, unrefreshing sleep, and cognitive fog. The criteria evolved toward the nervous system because that is where the illness kept pointing.

In 1990 a committee led by the rheumatologist Frederick Wolfe published the first widely accepted standard, the American College of Rheumatology criteria for the classification of fibromyalgia. It required widespread pain for at least three months plus tenderness at eleven of eighteen specified body points on examination. Those tender points gave the condition something it had never had, which was a positive finding rather than a list of exclusions.

They also caused two decades of trouble. Tender point counts varied with examiner pressure, with the patient's distress on the day, and with sex. The criteria had been designed to classify patients for research, and they migrated into the clinic as a pass or fail exam. People who plainly had the illness failed the count and were sent away.

Wolfe's group corrected course. The 2010 preliminary diagnostic criteria abandoned the tender point exam entirely, replacing it with a widespread pain index counting painful body regions and a symptom severity scale rating fatigue, waking unrefreshed, and cognitive symptoms. The 2016 revisions to those criteria tightened the definition of widespread and removed the requirement that other disorders be excluded, recognizing that fibromyalgia often sits alongside other diagnoses rather than competing with them.

Look at what the definition became. Pain in many regions, fatigue, unrefreshing sleep, and cognitive fog, scored together. That is a description of a regulatory state, not of a tissue.

Wolfe's own challenge to the label

Wolfe himself has been the sharpest critic of treating any of this as a clean biological boundary. In an essay on culture, science and the changing nature of fibromyalgia, written with the rheumatologist Brian Walitt, he pressed a further argument. Fibromyalgia's standing as a real disease, they wrote, is buttressed by social forces as much as by biology.

They listed the official criteria themselves, patient and professional organizations, pharmaceutical companies, disability access, and the legal and academic communities. They drew a deliberate parallel with neurasthenia, a label that once organized a great deal of genuine suffering and then dissolved.

The argument deserves engagement rather than offense. A diagnosis can be shaped by its own history and still name something measurable. Where a line gets drawn on a distribution is always partly a decision. Blood pressure is continuous, and hypertension is still real. What sits underneath the fibromyalgia label is a state of the system that instruments can read, and they have read it.

The sympathetic drive in fibromyalgia stays up through the night

Fibromyalgia patients fail to make the normal nocturnal shift toward vagal dominance, shown in 24-hour heart rhythm recordings, and a tilt-table challenge to their circulation worsens their body pain in real time. One dysregulated control system accounts for symptoms no muscle theory can touch.

Pain is one output of this illness, and if it were the only one the story could stop at the spinal cord. It is not. Patients report fatigue, dizziness on standing, gut disturbance, temperature intolerance, dry eyes and mouth, palpitations, and a body that behaves as though it is braced. Those symptoms belong to the autonomic nervous system, the division that runs organs, vessels, and glands without conscious command.

It has two branches. The sympathetic branch mobilizes: it speeds the heart, tightens vessels, mobilizes fuel, and sharpens vigilance. The parasympathetic branch restores, running mainly through the vagus nerve, which slows the heart, supports digestion, and rebuilds. The two are not a seesaw; they vary independently, and the autonomic nervous system page teaches that anatomy in full. Health is a fast, fluent exchange between them, sized to the moment.

That exchange can be measured. Every heartbeat is followed by a slightly different interval, and the pattern of that variation, called heart rate variability, is a validated index of autonomic state, particularly of the vagal brake's activity. Heart rate variability being an index of autonomic control is established physiology. Reading it as a window onto tone is this model's interpretation, and it is stated as such.

The recordings: no nocturnal handover

The Mexican rheumatologist Manuel Martinez-Lavin asked whether fibromyalgia patients differ on that measure. His group recorded heart rhythm across full twenty-four hour cycles, and their 1998 circadian study of autonomic balance in fibromyalgia found that patients failed to show the normal nocturnal shift toward vagal dominance.

The sympathetic drive stayed up through the night. He went further in a paper proposing that autonomic dysfunction may explain the multisystem features of fibromyalgia. One dysregulated control system accounts for the pain, the fatigue, the sleep failure, and the gut and circulatory symptoms at once. No muscle-based theory can do that.

The finding replicates with the usual biological scatter. The Belgian researcher Mira Meeus pooled heart rate variability studies in fibromyalgia and chronic fatigue syndrome in 2013. The review found reduced variability and a pattern consistent with sympathetic predominance across most studies, with heterogeneity between them. The pattern is real and it is not uniform, which is what a model of coupled regulation predicts: an input meets a tone, and the tone varies from patient to patient.

The tilt table: one challenge, two systems answering

The provocation studies are more striking than the resting ones. A tilt table test is simple to picture. You are strapped to a table that tilts you from lying to nearly upright while heart rate and blood pressure are recorded, which challenges the autonomic system to hold pressure against gravity.

The researcher Issam Bou-Holaigah ran that test in adults with fibromyalgia. The 1997 study of provocation of hypotension and pain during upright tilt testing found that patients dropped their blood pressure abnormally often. Many reported their widespread pain worsening during the tilt itself.

Read that last detail again, because it is the whole thesis in one observation. A postural challenge to the circulatory control system made the body pain worse in real time. Under a tissue model that is incoherent. Under a model where one organization sets both, it is exactly what you would predict.

Deep sleep loss produces fibromyalgia's symptoms in healthy people

In 1976 Harvey Moldofsky selectively deprived healthy volunteers of stage-four sleep and produced diffuse aching, tenderness, and fatigue within days. Restoring the sleep resolved it. That is an experiment with a direction, not a correlation.

Nearly every person with fibromyalgia describes sleep that returns nothing. They sleep and wake unrestored, stiff and aching, as though the night charged them rather than paying them.

The Toronto sleep researcher Harvey Moldofsky went looking for that in the recordings. Sleep is not one state. It cycles through stages, and the deepest non-REM stages, marked by slow, large brain waves, are when the most physical restoration happens. Wakefulness has a faster rhythm called alpha.

In 1975, studying patients then labeled with fibrositis, Moldofsky recorded overnight brain activity and found alpha rhythm intruding into deep non-REM sleep. His report of musculoskeletal symptoms and non-REM sleep disturbance showed that the intrusion tracked morning pain and stiffness. The body lay asleep while part of the brain stayed on watch.

The deprivation experiment settled the direction

An association like that can always be dismissed as pain wrecking sleep. Moldofsky went after the direction of causation the only way that settles it. He recruited healthy volunteers with no pain complaint and selectively deprived them of deep stage-four sleep, waking them with a tone whenever the deep rhythm appeared while leaving total sleep time largely intact.

The result, published as the induction of neurasthenic musculoskeletal pain by selective sleep stage deprivation, was that ordinary healthy people developed diffuse musculoskeletal aching, tenderness, and fatigue within days. Restore the sleep and it resolved.

He had produced the syndrome's core features in healthy subjects by manipulating one regulatory variable.

Later work sharpened it. The German pain researcher Sigrid Schuh-Hofer tested whether even a single bad night moves pain sensitivity. In 2013 she found that one night of total sleep deprivation promotes generalized hyperalgesia, lowering pain thresholds across body sites in healthy volunteers.

And the Norwegian epidemiologist Paul Jarle Mork followed 12,350 women who had no fibromyalgia, no musculoskeletal pain, and no physical impairment at the start, then checked back roughly a decade later. His analysis of sleep problems and the risk of fibromyalgia found a dose-dependent relationship, with women reporting frequent sleep problems carrying about three and a half times the risk of developing the illness.

Sleep is when the nervous system resets its own gain. Take away the reset and the gain drifts up in anyone. Take it away for years and you get a system that has forgotten where its baseline was.

Small-fiber pathology is present in about half of fibromyalgia patients

Skin biopsies from three independent groups, published within roughly a year of each other, found thinned small nerve fibers in fibromyalgia, and a 2019 meta-analysis put the pooled prevalence near 49 percent. Something objectively measurable is different in the peripheral nerves of a large fraction of these patients.

The thinnest nerve fibers in the body, called small fibers, carry pain and temperature signals from the skin and also carry autonomic instructions to sweat glands and small blood vessels. They are too fine to show up on the standard nerve conduction test, which is why a patient can be told their nerve testing is normal while these fibers are quietly abnormal. They can be counted directly by taking a punch of skin about three millimeters across and staining the nerve endings under a microscope.

Three groups did that in fibromyalgia within roughly a year of each other. The German neurologist Nurcan Üçeyler examined skin biopsies alongside functional testing and reported small fibre pathology in patients with fibromyalgia syndrome, with reduced nerve fiber density and impaired small fiber function compared with controls.

The Boston neurologist Anne Louise Oaklander tested whether a definable neuropathy was hiding inside the label. She found objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia, in roughly two of five patients studied. Small-fiber polyneuropathy is a findable, sometimes treatable diagnosis, and in that fraction of patients the label fibromyalgia had been covering it.

The Spanish neurophysiologist Jordi Serra went further and listened to the fibers directly. Microneurography involves sliding a fine electrode into a nerve in an awake person and recording from individual fibers, one at a time. His 2014 study of hyperexcitable C nociceptors in fibromyalgia found nociceptors firing spontaneously, with no stimulus at all, and firing too easily when stimulated.

A meta-analysis led by the researcher Rebecca Grayston pooled the biopsy and corneal imaging studies. It found a pooled prevalence of small fiber pathology of about 49 percent, with wide confidence intervals and substantial heterogeneity between studies.

What the model does with the periphery

The Unified Model of Tone reads the small fibers the way it reads everything else: an input meets a tone. In the patients where small-fiber polyneuropathy is the driver, a degraded peripheral report is arriving at a spinal checkpoint that amplifies it, and finding that neuropathy matters because some of its causes are treatable.

In the rest, the thinned endings read as a consequence rather than a cause, because chronic sympathetic drive controls the skin's small vessels and the nerve endings that live among them. The same organization that holds the gain up reshapes the tissue reporting to it. Input quality and gain are coupled, and a distortion held long enough writes itself into both.

Small fiber loss also occurs in diabetes and in healthy aging, and it does not by itself produce widespread body pain, which is why the biopsy is a clue rather than a verdict. What the finding removes for good is the last version of the accusation. Something objectively measurable is different in the peripheral nerves of a large fraction of these patients. That was never supposed to be there.

The starting settings decide what the trigger does

Fibromyalgia follows infection, surgery, car crashes, bereavement, insomnia, and unrelenting stress, triggers with nothing in common at the level of tissue and one thing in common at the level of regulation. Each is a sustained demand on the system that sets protection.

The pattern shows up prospectively. A Manchester epidemiology group led by A. Gupta followed people who were free of chronic widespread pain and watched who developed it. The 2007 study of psychosocial factors predicting the onset of chronic widespread pain found that sleep disturbance, illness behavior, and somatic symptom reporting predicted onset before any pain existed. The vulnerability preceded the illness.

Early adversity shows up too, with its effect size attached. The German physician Winfried Häuser led a systematic review with meta-analysis on emotional, physical, and sexual abuse in fibromyalgia syndrome. It found associations between reported abuse and the diagnosis, with modest effect sizes and methodological limits across the source studies. This is a risk factor of moderate size in populations, and it says nothing about any individual person. Most people with fibromyalgia have no such history, and having such a history is not a diagnosis.

Some of the variation is written in the genome. The geneticist Luda Diatchenko examined variants of an enzyme called COMT, which clears catecholamines such as adrenaline and noradrenaline from the nervous system. Her 2005 work on the genetic basis for individual variations in pain perception found that particular haplotypes predicted how sensitive a healthy person was to experimental pain. The same haplotypes predicted who went on to develop a chronic pain condition. People are not issued identical pain systems.

Put those three together and you have the shape of it. Different people carry different starting settings. The same input lands on those different settings and produces different results. The event does not contain the outcome. The meeting does.

One organization, read in seven measurements

Amplified spinal processing, augmented brain response, failed descending inhibition, activated glia, autonomic imbalance, fractured sleep architecture, and thinned nerve endings sit in different journals because they belong to different specialties. The Unified Model of Tone reads them as one thing.

Tone is the integrated, coupled organization the nervous system holds across all of its systems at once, and the range that organization can move through. A healthy nervous system runs a wide, flexible range. It can raise protection sharply when a threat is genuine, then release it completely when the threat passes.

It can drive the heart hard up a staircase and let it settle at the top. It can go deeply asleep and come fully awake. The width of that range is what health is. Tone that collapses out of that range, into a setting it can no longer leave, is what manifests as illness.

Fibromyalgia is the purest expression of that collapse anywhere in medicine. The gain has risen and stayed risen. The range has narrowed to a permanently raised, permanently costly setting. Nothing is broken because a setting is not a part. That is the whole account of why the tests are clean. It is a prediction of what the tests should show, and they show it.

The chord: seven readouts of one organization

The second move matters as much. Any measured variable here is a chord, not a note. The pain a person reports is sounded together by many voices. The nociceptors at the periphery, the gain at the spinal checkpoint, the strength of the descending brake, and the activation state of the glia.

The autonomic balance of the moment, last night's sleep architecture, and the running prediction of how dangerous the situation is. All of those voices are coupled. They are seven readouts of one organization, carried in different mediums, rather than seven separate problems that happened to co-occur in the same patient.

The tone of the nerve ending, the tone of the cord, the tone of the brake, the tone of the vagus, the tone of the sleeping brain. One organization, sounding in seven registers, which is why fixing one register never fixes the chord.

What the single variable explains

Watch how much this dissolves at once. Fibromyalgia is unexplained because the fault is in the tuning across a coupled system, and every diagnostic tool medicine owns is built to photograph parts. It is widespread because gain is a property of the system rather than a location in it, so it does not respect anatomical borders. It comes with fatigue, gut trouble, dizziness, and fog because those systems are voices in the same chord.

It follows infection, trauma, grief, and insomnia because those are inputs to the regulator, and an input meets a tone. It varies enormously between people because the tone it meets varies. It gets worse under stress and better on holiday because tone tracks demand. It is more common in women and clusters in families because starting settings differ.

Unification has been attempted before, and the precedent supports the reading. The psychophysiologist Julian Thayer and the psychiatrist Richard Lane proposed a model of neurovisceral integration, in which one network links attention, emotion regulation, and autonomic control. Their proposal points at the same missing variable. This model names it, and extends it to the pain system and the sleeping brain as well.

The claim is stated plainly as the model's own. Established science says the pain processing system is sensitized in fibromyalgia and that autonomic, sleep, immune, and peripheral abnormalities accompany it. This model says otherwise: they are the same variable seen from different angles, and the variable is tone.

What the fibromyalgia drugs do, and what they leave in place

Pregabalin produces major pain relief in roughly ten percent more people than placebo, and the SNRIs show no clinically relevant benefit for fifty percent relief. Both push one voice in the chord, for as long as the dose continues, and neither moves the setting.

Consider what the licensed medications actually do. Pregabalin dampens excitatory transmitter release at overactive nerve terminals. Duloxetine and milnacipran raise serotonin and noradrenaline levels, strengthening the chemistry the descending brake uses. Both are aimed intelligently at the mechanism, which is more than can be said for most historical fibromyalgia treatments. Both are legitimate medicine and both help some people meaningfully.

The measured performance

A Cochrane review of pregabalin for pain in fibromyalgia was led by the pain researcher Sheena Derry. It concluded that pregabalin at 300 to 600 milligrams produces a major reduction in pain for a small proportion of people, roughly ten percent more than placebo.

A Cochrane review of serotonin and noradrenaline reuptake inhibitors for fibromyalgia was led by the researcher Patrick Welsch. On low to very low quality evidence, it found no clinically relevant benefit over placebo for fifty percent pain relief. It did find a clinically relevant benefit for global improvement and for thirty percent relief.

Nothing about those numbers is scandalous. They are ordinary numbers for a drug aimed at a chronic condition. What they describe is a particular kind of action. A drug of this class pushes the output in one direction. It lowers a signal, or it raises a transmitter. It is a hand on one voice in the chord, held there for as long as the dose continues, and when the dose stops the setting is where it was.

Masking and restoring name two different targets

The model calls that masking, and the word is descriptive rather than dismissive. Masking is often the right call. A person in severe pain who cannot sleep or work needs the output managed now, and medication has a real and honorable place in fibromyalgia care.

Restoring is a different target. Restoring means widening the range the system can move through, so that the gain comes down because the regulator recovered its ability to stand down. A restored system does not need the hand held on the voice. It sleeps deeply and wakes rested. It raises protection when something genuinely threatens and releases it afterward. Its pain thresholds return toward the ordinary population middle rather than being chemically blunted past it.

Those two states look similar on a pain scale at week twelve. They are entirely different states of the system, and they behave differently over years. Distinguishing them requires a test, and the model has one.

The prediction that would prove the tone reading wrong

Fibromyalgia patients are uniform on the complaint and opposite on the measurements: some run tachycardia and some bradycardia, some drop pressure on standing and some hold it high. The model predicts a genuine tonal correction moves each group toward the middle from its own side. A drug cannot do that.

A drug is directional by construction. A drug that lowers a value lowers it in everybody who responds, including people in whom that value was already low. That is what a pharmacological agent is. Push, one way.

A genuine restoration of tone is not directional. It moves a dysregulated value toward the healthy middle from whichever side that person is on. If your value is too high it comes down. If your value is too low it comes up. The endpoint is the middle of the range, because the thing being corrected is the regulator's ability to find the middle rather than the height of the number.

Why fibromyalgia is the right arena

Fibromyalgia offers an unusually good arena to test this, because these patients are not uniform on the measurable variables even though they are uniform on the complaint. Some run resting tachycardia and some run bradycardia. Some drop their blood pressure on standing, as the tilt table work showed, while others hold it high. Some are hypervigilant and wired at night, some are flattened and unable to mount a response to anything. Some show blunted cortisol rhythms and some show exaggerated ones. Same diagnosis, opposite deviations.

So the model states a specific prediction. Apply a genuine tonal correction across a mixed group of fibromyalgia patients and measure the autonomic variables before and after. The tachycardic should slow and the bradycardic should rise. The orthostatic droppers should hold pressure better and the pressure-holders should relax.

The low-variability group should gain variability toward normal without the already-normal group overshooting. Group averages should barely move while the spread around the middle should shrink measurably. A one-directional agent cannot produce that pattern, and neither can regression to the mean, which does not produce coordinated movement across coupled systems in step with symptom change.

What each result would mean, stated in advance

The readings are fixed before the data arrive. An input that only ever pushes values in one direction is managing an output rather than restoring the regulator, and in a mixed group it carries half the patients further from the middle. Measured regulation means variability, sleep architecture, orthostatic stability, and pain thresholds.

When those measures move and symptoms move with them, the central claim is confirmed. When the sleep, the autonomic findings, and the cognitive symptoms track one regulatory disturbance rather than one findable peripheral lesion, the model is confirmed. Those experiments are all runnable with instruments that exist today.

A drug moves the number. A restored tone moves the range. The difference shows up in the direction people travel from opposite starting points.

Exercise holds the only strong recommendation in fibromyalgia

The EULAR guideline reviewed the whole evidence base and issued exactly one strong recommendation, for exercise, while every pharmacological recommendation came out weak. That is a striking verdict for a condition managed largely with prescriptions, and the model predicts it.

The EULAR revised recommendations for the management of fibromyalgia, a European society guideline led by the epidemiologist Gary Macfarlane, is the document behind that verdict. The treatment literature it reviewed is genuinely mixed. The model reads the mixture the same way it reads everything else: each input lands on a different tone, so pooled averages blur what individual systems did.

Exercise works at the right dose and flares at the wrong one

The exercise evidence itself is modest. A Cochrane review of aerobic exercise training for adults with fibromyalgia was led by the researcher Julia Bidonde. It found moderate-quality evidence that aerobic exercise probably improves health-related quality of life, and low-quality evidence that it may slightly reduce pain and slightly improve function. Slightly is the word the reviewers used, and it stands. There is also a practical problem the reviews cannot fully capture.

Exercise prescribed at a normal intensity to a sensitized nervous system frequently makes things worse for days, which is how many patients learn to fear the one intervention with the strongest recommendation behind it. Graded means starting below the level that provokes a flare and rising slowly enough that the system never registers the increase as a threat. That detail is the difference between the intervention working and the patient quitting.

Gentler movement performs at least as well. The rheumatologist Chenchen Wang ran a randomized trial in the BMJ comparing tai chi against aerobic exercise for fibromyalgia. Tai chi produced improvement similar to or greater than aerobic exercise, and longer programs performed better. Tai chi is slow, low-threat, breath-paced movement with a large postural and attentional component. Under this model that ranking makes sense. It is an input that trains range without triggering the alarm.

Therapy aimed at the constructing system

Psychological therapy has a small effect that is real. A Cochrane review of cognitive behavioural therapies for fibromyalgia, led by the psychologist Kathrin Bernardy, found small incremental benefits over control conditions for pain, mood, and disability, sustained at long-term follow-up. Small and durable. This is also the point where the model is explicit.

A treatment that works partly through the brain is not evidence that a condition was invented by the brain. Pain is constructed in the nervous system in every human being, including the ones with a broken femur. An intervention aimed at the constructing system is aimed at the mechanism.

Inputs aimed at the regulator itself

Interventions aimed directly at the regulator are earlier stage, and the evidence is preliminary. Heart rate variability biofeedback trains a person to breathe at a rate that maximizes the natural rhythm linking breath and heartbeat.

The psychologists Paul Lehrer and Richard Gevirtz have described how and why that training changes autonomic function, most plausibly by exercising the reflex arcs that regulate the circulation. A pilot study by the psychologist Afton Hassett testing heart rate variability biofeedback in patients with fibromyalgia reported improvements in pain, function, and depression.

It was small and uncontrolled, and it proves nothing on its own. A phase one and two proof-of-concept trial of vagus nerve stimulation in fibromyalgia, run by the researcher Gudrun Lange, found symptom improvement in a small open-label sample. Also preliminary. Both are named here as directions to test, and the model's own bidirectional prediction has not yet been formally run in this population.

Sleep belongs on this list even though it is rarely written as a prescription. Given Moldofsky's induction experiment and Mork's prospective data, treating sleep as a symptom to be waited out is a mistake. It is an input to the regulator with demonstrated power to move the whole picture in both directions.

The boundary that never moves

Findable causes must still be found. Hypothyroidism, inflammatory arthritis, polymyalgia rheumatica, myositis, sleep apnea, anemia, vitamin D and B12 deficiency, celiac disease, and drug side effects can all produce widespread pain and fatigue. Every one of them is treatable when identified.

A fibromyalgia diagnosis is not a reason to stop looking, and the tone reading demands a more thorough workup, never a thinner one. Nothing here is a treatment recommendation for any individual, and nobody should start, stop, or change a treatment based on a web page.

Four objections to the tone reading of fibromyalgia, answered

Causation, relabeling, prediction, and anti-medicine are the four objections this reading of fibromyalgia has to answer, and each answer comes with an experiment or a named boundary attached.

These are correlations, so where is the cause?

Some are not correlations. Moldofsky deprived healthy people of deep sleep and produced the symptoms, then restored the sleep and resolved them. Schuh-Hofer removed one night of sleep and moved pain thresholds. Mork followed twelve thousand pain-free women forward in time and found sleep problems preceding the illness in a dose-dependent way. Woolf changed spinal cord excitability experimentally and produced pain from harmless input.

Those are manipulations with a direction. For the remaining findings the model does not claim one voice causes the others, because it holds they are coupled readouts of one organization, which is a different claim requiring a different test. That test is the bidirectional prediction in section thirteen, and instruments that already exist can run it.

Is tone a new label for central sensitization?

No, and the difference matters. Central sensitization is a specific, well-characterized mechanism in the dorsal horn and brain, and this model accepts it entirely as established science. Tone is a broader claim: the same organization sets the spinal gain, the autonomic balance, the sleep architecture, the immune activation state, and the peripheral nerve environment together, in step.

Central sensitization explains why a light touch hurts. It does not explain why the same patient cannot sleep, cannot stand up without dizziness, cannot regulate temperature, and cannot think clearly. The unification is the contribution.

If tone explains everything, does it predict anything?

It predicts a specific pattern that a directional treatment cannot produce, described in section thirteen. It predicts that measures of regulation should carry information about symptoms rather than being unrelated to them, while compensation can hold symptoms quiet after regulation has begun to drift, and can hold a measure steady while symptoms move.

It predicts that inputs which restore sleep and autonomic range should improve pain in a population where no analgesic mechanism was involved, which the exercise, tai chi, and sleep literature already partly supports. Each of those can come out the other way. That is the point of stating them.

Is this an argument against medicine?

It is an argument against one method being treated as the whole of knowledge. The method that looks for a broken part is superb and it should never be abandoned, because it is the method that finds the thyroid disease, the myositis, and the tumor. Its limitation is structural and it is only this: it cannot see a setting.

Medications for fibromyalgia have a real place, and for some people they are the reason life is livable. Cognitive therapy has a real place. The model's disagreement is with one inference, that a normal test means an absent illness. The field has already abandoned that inference, which is precisely why nociplastic pain now exists as a category.

Recovery of tone in fibromyalgia is measurable with existing instruments

Heart rate variability, quantitative sensory testing, conditioned pain modulation, overnight polysomnography, tilt testing, skin biopsy, and actigraphy each read one voice of the organization, and every one of them exists in laboratories today.

Heart rate variability reads the flexibility of the vagal brake, and it is a validated index of autonomic state. Quantitative sensory testing reads pain thresholds and wind-up directly, so the amplification Staud measured in 2001 can be tracked rather than inferred. Conditioned pain modulation tests whether the descending brake engages, which is the deficit Julien identified in 2005.

Overnight polysomnography reads whether deep sleep is intact or invaded, which is where Moldofsky's work began in 1975. Tilt testing reads whether the circulatory system can hold its range against gravity. Skin biopsy reads the nerve endings. Actigraphy reads whether the day and night have separated again.

A nervous system that is regaining its range shows it on those instruments, and it shows it in a particular way. Variability rises toward the middle rather than past it. Deep sleep returns and alpha intrusion recedes. Thresholds normalize rather than climbing indefinitely. Orthostatic responses converge from both directions. Symptoms move in step with the measurements rather than independently of them.

The definitive question is still open. Nobody yet knows how much of fibromyalgia can be reversed by restoring regulation rather than damping its output, because the trial that would settle it, with the bidirectional analysis built in, has not been run. That is a question this model is eager to be asked.

What is already settled is smaller and it matters more to the person reading this. The pain is real, it has a mechanism, and the mechanism has been measured in laboratories on four continents. The normal test results were never evidence against the illness. They were evidence about where the illness lives. It lives in the regulation, and regulation is the one thing in the body that was always meant to be able to change.

How fibromyalgia relates to the rest of the library

Fibromyalgia sits where the foundations of tone meet the conditions of protection, and each neighboring page carries one piece of its story.

Four condition pages border this one.

• Pain holds the full teaching of the protective output this page could only summarize: the neuromatrix, the gate, and the alarm's construction.
• Sleep holds the machinery whose deepest stages reset the gain, the reset Moldofsky removed from healthy volunteers to produce this syndrome.
• Unexplained symptoms is the wider territory fibromyalgia is the prototype of: real illness in the regulation, invisible to tests built for parts.
• Dysautonomia is where the autonomic findings of section seven become the presenting problem rather than the accompaniment.

Two more pages complete the picture. Heart rate variability is the instrument behind the 24-hour recordings that caught the sympathetic drive failing to stand down at night, and its page explains what one autonomic channel can and cannot see. Long COVID is the newest condition following fibromyalgia's template: a trigger, a nervous system that does not stand down afterward, and a clean set of standard tests.

Frequently asked